The combination of pirtobrutinib, venetoclax, and rituximab was very effective and produced deep remissions in patients with relapsed / refractory CLL.
Early research suggests that exercise increases the number of immune cells in the blood and increases the ability of rituximab to kill CLL cells
Rituximab can be given in combination with many other medications to treat CLL or SLL.
With the introduction of BTK inhibitors to treat CLL, there has been no disparity in survival outcomes for patients of different races and ethnicities.
In this final long-term analysis of the groundbreaking MURANO trial, progression-free survival (PFS) and overall survival (OS) benefits for venetoclax-rituximab (VenR) over bendamustine-rituximab (BR) were once again confirmed.
Study shows that patients with relapsed/refractory CLL recovered immune function after fixed-duration treatment with venetoclax + rituximab.
At the 2021 annual meeting of the American Society of Hematology, CLL Society’s Medical Advisory Board Co-Chair Dr. Alex Danilov interviewed Dr. Arnon P. Kater, the lead author of this article and Chair of the Dutch CLL society, to discuss the evolving results of the Murano trial four years later. Please enjoy this interview and article about very hopeful treatment.
Acalabrutinib plus high-frequency, low-dose subcutaneous rituximab is tolerable and effective. In addition, because it can be administered at home, it is more convenient and can decrease patient infection risk during pandemics. However, while it does control disease, it does not lead to undetectable measurable residual disease (uMRD).
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911
